← Leaderboards
James S Hagood
University Of Alabama At Birmingham
$12,535,112
Attributed
$15,787,047
Total exposure
11
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,332,395 · 12
By mechanism
R01$8,033,693 · 4
U54$6,524,059 · 2
U01$3,686,905 · 1
P01$2,547,820 · 1
R03$284,284 · 2
P60$232,634 · 1
Top collaborators
- Sanjay Jain6 shared
- Xin Sun6 shared
- Kun Zhang6 shared
- Namasivayam Ambalavanan5 shared
- Naftali Kaminski5 shared
- Peter V Kharchenko5 shared
- Bogdan Olenyuk2 shared
- Ruslan Soldatov1 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Anne C. Woods$2,657,007
- Charitharth Vivek Lal$838,080
- Rui-Ming Liu$7,365,974
- Elizabeth Ann Eklund$14,527,585
- John Paul Clancy$7,228,581
Others in their field
Top investigators on “Lung”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$372,040,227
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$201,818,043
- Walter John Curran · Thomas Jefferson University$112,093,071
Research focus
LungCellsPhenotypeLung DiseasesFibroblastsTissuesFibrosisProteinsRegulationAnimal ModelMediatingIn VitroFibrogenesisProgramsMolecularHamman-Rich SyndromeHuman TissueLaboratoriesSignal TransductionBiologicalAffectInflammatoryMyofibroblastIn Vivo
Grant awards (49)
Localizing Therapeutics to Target Lung Myofibroblasts and Reverse Fibrosis$782,151
R01 · FY2025 · HL
Localizing Therapeutics to Target Lung Myofibroblasts and Reverse Fibrosis$805,845
R01 · FY2024 · HL
KULMAP: Human Kidney, urinary tract and lung mapping center$1,848,510
U54 · FY2021 · HL
Organ Specific Project$310,466
U54 · FY2021 · HL · contact PI
KULMAP: Human Kidney, urinary tract and lung mapping center$100,000
U54 · FY2021 · HL
KULMAP: Human Kidney, urinary tract and lung mapping center$1,846,838
U54 · FY2020 · HL
Organ Specific Project$311,221
U54 · FY2020 · HL · contact PI
KULMAP: Human Kidney, urinary tract and lung mapping center$1,000,000
U54 · FY2019 · HL
Targeting Anti-Fibrotic Therapies for IPF$505,077
P01 · FY2019 · HL · contact PI
Organ Specific Project$194,524
U54 · FY2019 · HL · contact PI
KULMAP: Human Kidney, urinary tract and lung mapping center$100,000
U54 · FY2019 · HL
Alveolar DevMAP$734,685
U01 · FY2018 · HL
KULMAP: Human Kidney, urinary tract and lung mapping center$650,000
U54 · FY2018 · HL
Targeting Anti-Fibrotic Therapies for IPF$506,214
P01 · FY2018 · HL · contact PI
Organ Specific Project$162,500
U54 · FY2018 · HL · contact PI
Alveolar DevMAP$742,417
U01 · FY2017 · HL
Targeting Anti-Fibrotic Therapies for IPF$505,087
P01 · FY2017 · HL · contact PI
Regulation of Fibroblast Phenotype in Lung Fibrosis$334,784
R01 · FY2017 · HL · contact PI
Alveolar DevMAP$734,777
U01 · FY2016 · HL
Targeting Anti-Fibrotic Therapies for IPF$505,093
P01 · FY2016 · HL · contact PI
Regulation of Fibroblast Phenotype in Lung Fibrosis$493,995
R01 · FY2016 · HL · contact PI
Alveolar DevMAP$734,976
U01 · FY2015 · HL
Regulation of Fibroblast Phenotype in Lung Fibrosis$548,433
R01 · FY2015 · HL · contact PI
Targeting Anti-Fibrotic Therapies for IPF$526,349
P01 · FY2015 · HL · contact PI
Targeting the Apoptosis-Resistant Pulmonary Myofibroblast$447,081
R01 · FY2015 · HL · contact PI
Alveolar DevMAP$740,050
U01 · FY2014 · HL
Targeting the Apoptosis-Resistant Pulmonary Myofibroblast$442,878
R01 · FY2014 · HL · contact PI
Regulation of Fibroblast Phenotype in Lung Fibrosis$425,985
R01 · FY2014 · HL · contact PI
Targeting the Apoptosis-Resistant Pulmonary Myofibroblast$366,282
R01 · FY2013 · HL · contact PI
Targeting the Apoptosis-Resistant Pulmonary Myofibroblast$69,750
R01 · FY2013 · HL · contact PI
Targeting the Apoptosis-Resistant Pulmonary Myofibroblast$383,925
R01 · FY2012 · HL · contact PI
Childhood Interstitial & Diffuse Lung Disease Scientific Conference$23,000
R13 · FY2012 · HL · contact PI
Regulation of Fibroblast Phenotype in Lung Fibrosis$385,954
R01 · FY2011 · HL · contact PI
Regulation of Fibroblast Phenotype in Lung Fibrosis$385,960
R01 · FY2010 · HL · contact PI
Regulation of Fibroblast Phenotype in Lung Fibrosis$363,120
R01 · FY2009 · HL · contact PI
Epigenetic Alterations in IPF Fibroblastic Foci$73,188
R03 · FY2009 · HL · contact PI
Regulation of Fibroblast Phenotype in Lung Fibrosis$18,134
R01 · FY2009 · HL · contact PI
Regulation of Fibroblast Phenotype in Lung Fibrosis$363,685
R01 · FY2008 · HL · contact PI
Regulation of Fibroblast Phenotype in Lung Fibrosis$358,457
R01 · FY2007 · HL · contact PI
Role of Fibroblast Thy-1 in Pulmonary Fibrosis$290,000
R01 · FY2005 · HL
Role of Fibroblast Thy-1 in Pulmonary Fibrosis$253,750
R01 · FY2004 · HL
Role of Fibroblast Thy-1 in Pulmonary Fibrosis$261,232
R01 · FY2003 · HL
Role of Fibroblast Thy-1 in Pulmonary Fibrosis$244,810
R01 · FY2002 · HL
FIBROBLAST CD 90 EXPRESSION IN FIBROGENIC SKIN DISORDERS$71,750
R03 · FY2002 · AR
Role of Fibroblast Thy-1 in Pulmonary Fibrosis$7,482
R01 · FY2002 · HL
FIBROBLAST CD 90 IN ARTHRITIS AND INFLAMMATORY DISORDERS$116,317
P60 · FY2001 · AR
FIBROBLAST CD 90 EXPRESSION IN FIBROGENIC SKIN DISORDERS$71,750
R03 · FY2001 · AR
FIBROBLAST CD 90 IN ARTHRITIS AND INFLAMMATORY DISORDERS$116,317
P60 · FY2000 · AR
FIBROBLAST CD 90 EXPRESSION IN FIBROGENIC SKIN DISORDERS$67,596
R03 · FY2000 · AR